

Tolfine

Variation	Summary	Date
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	17/08/26
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	01/05/26
Vet - B3 d)	VNRA - Vet - B3 d) - - Vet - B3 d) - Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) of — an active substance;— a starting material;— an intermediate or reagent used in the manufacturing process of the active substance	25/02/26
Vet - F.I.a.1 a)	VRA-S - Vet - F.I.a.1 a) - - Vet - F.I.a.1 a) - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	28/07/25
Vet - G.I.19	VRA-R - Vet - G.I.19 - G.I.19 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6 - G.I.19 - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6	28/08/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	31/03/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered	31/03/23

	elsewhere in the Annex to Regulation (EU) 2021/17	
Vet - F.II.f.1 a) 1.	VRA-R - Vet - F.II.f.1 a) 1. - a) Extension of the shelf life of the finished product 1. As packaged for sale (supported by real time data) - F.II.f.1 a) 1. Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	09/03/23
Vet - B47 c)	VNRA - Vet - B47 c) - c) Change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur. - B47 c) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur.	17/02/23
B.III.1.a.1	IAin - B.III.1.a.1 - 1. New certificate from an already approved manufacturer - B.III.1.a.1 - QUALITY CHANGES - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. Certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance For a starting material/reagent/intermediate used in the manufacturing process of the active substance For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	28/01/22